Key result
SGLT2 inhibitors linked to ~1.0-kg greater Day 1 weight loss in diuretic-resistant ADHF.
Why the study?
Diuretic resistance is common in ADHF, and recommended thiazide adjuvants have side effects and are tied to worsened survival, prompting evaluation of SGLT-2i's as alternative diuretic adjuvants.
Does the addition of SGLT-2 inhibitors improve weight loss and urine output in patients with acute decompensated heart failure and loop diuretic resistance?
Observational (n=31)
No
Does the addition of SGLT-2 inhibitors improve weight loss and urine output in patients with acute decompensated heart failure and loop diuretic resistance?
SGLT-2 inhibitors may safely enhance urine output and weight loss in patients with ADHF exhibiting diuretic resistance without worsening renal function or hemodynamics.
Answers are grounded in this paper and cite their sources.
May support adjunctive SGLT-2i in diuretic-resistant ADHF; leaves open confirmation in randomized trials.
AIMS: Diuretic resistance is common in acute decompensated heart failure (ADHF). When loop diuretic monotherapy is ineffective, thiazides are often recommended as adjunctive therapy, but these agents have many side effects and are associated with worsened survival. In contrast, sodium glucose cotransporter 2 inhibitors (SGLT-2i's), initially developed as glucose-lowering medications for type 2 diabetes, improve heart failure outcomes. A candidate contributory mechanism for this benefit is their diuretic effects. We sought to describe the safety and efficacy of SGLT-2i's as loop diuretic adjuvants in ADHF. METHODS AND RESULTS: We retrospectively analysed patients who received adjuvant SGLT-2i therapy between August 2016 and June 2018 at Yale-New Haven Hospital. Thirty-one patients comprised the cohort, 58% of whom had type 2 diabetes. Compared with the 24 h prior to SGLT-2i initiation, average weight loss improved (1.0 ± 2.2 kg, P = 0.03 at Day 1; 1.7 ± 4.9 kg, P = 0.08 at Day 2; and 2.1 ± 5.6 kg, P = 0.06 at Day 3), as did urine output (3.7 ± 2.0 L, P = 0.002 at Day 1; 3.4 ± 1.7 L, P = 0.02 at Day 2; and 3.1 ± 1.7 L, P = 0.02 at Day 3) while loop diuretic dosing remaining stable. Creatinine remained unchanged during the 3 days after initiation, as did blood pressure and the incidence of hypokalaemia (P = NS for all). CONCLUSIONS: In this cohort of patients with ADHF, SGLT-2i's improved weight loss, urine output, and diuretic efficiency without worsening of creatinine, potassium, or blood pressure. Further study of SGLT-2i's as a loop diuretic adjuvant is warranted.
No takes yet. Share an insight, caveat, or question.
Griffin et al. (2020) conducted an observational in Acute Decompensated Heart Failure (ADHF) with diuretic resistance (n=31). SGLT-2 inhibitors (canagliflozin or empagliflozin) was evaluated on Change in average weight at Day 1 compared to 24 hours prior (MD 1.0, p=0.03). In patients with acute decompensated heart failure and diuretic resistance, SGLT-2 inhibitor therapy improved weight loss and urine output on Day 1.
Synapse has enriched 10 related papers. Consider them for comparative context: